Triple combination ivacaftor + tezacaftor + elexacaftor and ivacaftor for cystic fibrosis: clinical efficacy and safety of the original drug and its generic analogue Trilexa®
Triple CFTR modulator therapy with ivacaftor + tezacaftor + elexacaftor and ivacaftor (ITE) has substantially changed the clinical course and prognosis of cystic fibrosis. The expanding use of the bioequivalent generic Trilexa® highlights the need to summarize evidence on its clinical efficacy and safety, including out...